TuHURA Biosciences (HURA) Financials

TuHURA Biosciences (NASDAQ: HURA) is still a pre-revenue biotech company with significant cash burn, but it has recently strengthened its balance sheet through equity financing. The latest quarter shows no revenue, a net loss of about $7.5 million, and negative operating cash flow of $4.4 million. At the same time, cash and equivalents rose to $6.3 million, helped by $7.5 million of common equity issuance during the quarter.

• Cash balance improved to $6.3 million at March 31, 2026, up from $2.7 million at the end of Q3 2025.
• Net cash from financing was strong in Q1 2026, with $7.1 million raised from financing activities.
• Common equity issuance provided fresh funding of $7.5 million in the latest quarter, supporting near-term liquidity.
• Operating cash burn was lower than the net loss, suggesting non-cash charges and working-capital movements helped offset some losses.
• Research spending remains high at $5.2 million in Q1 2026, which is typical for a development-stage biotech but keeps expenses elevated.
• The company generated no revenue in the latest quarter, so progress still depends on clinical and financing milestones rather than operating sales.
• Quarterly EPS was -$0.13, roughly in line with the ongoing loss profile.
• Shares outstanding remain elevated at about 60.0 million basic shares, indicating dilution pressure from financing activity.
• Operating losses continue, with Q1 2026 operating expenses of $7.5 million and no gross profit to offset them.
• Balance sheet leverage remains meaningful: total liabilities were $6.5 million versus cash of $6.3 million, leaving limited financial cushion.

Looking at the broader trend, HURA’s financial profile has been volatile but consistently loss-making. Quarterly operating losses have generally stayed in the $3 million to $10 million range over the last year, and the company has relied on external capital to fund operations. Cash has swung sharply quarter to quarter, which is common for biotech firms but also signals dependence on financing markets.

One positive trend is that liquidity appears better than it was a year ago. As of early 2025, cash was just $216,000 in Q1 2024 and $6.2 million in Q1 2025. Recent financing activity helped rebuild cash, but the company is still burning several million dollars per quarter, so investors should expect additional funding needs unless operating performance improves materially.

Bottom line: TuHURA Biosciences has improved its short-term cash position, but the core story is still high burn, no revenue, and ongoing dilution risk. For retail investors, the stock remains highly speculative and likely to trade on clinical and financing developments rather than traditional earnings momentum.